On April 18, 2024, the US Food and Drug Administration (FDA) announced the approval of alectinib to treat patients after surgical removal of ALK-positive non-small cell lung cancer (NSCLC).
The approval is supported by data from the phase 3 ALINA trial, which showed that treating patients with alectinib reduced the risk of disease recurrence by 76% compared to treating them with chemotherapy.
Alectinib is approved for use in patients with completely resected stage IB to IIIA ALK-positive NSCLC whose tumors are at least 4 cm wide.
This targeted therapy has already been approved by the FDA to treat metastatic ALK-positive NSCLC.
For more details, including common side effects, please see the FDA press release.
You can find additional information about this FDA approval in the newsfeed on this website.